The purpose of this study is to assess the palatability of eliglustat prototype liquid
formulations in healthy subjects.
The total duration of the study for each subject will be approximately 5 weeks (screening
period from Day -28 to Day -2, treatment period of 3 days, and follow-up call on Day 5).
Inclusion criteria :
- Healthy male and female subjects, 18 to 55 years of age, inclusive.
- Normal smell and taste ability to discriminate odor and flavor differences.
- Poor metabolizer phenotype status for CYP2D6 (predicted based on genotype).
- Subject who has smoked within 3 months of inclusion.
The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.